-
Coronary artery stenoses involving the proximal left anterior descending coronary artery (LAD) have caused significant concern for clinicians over the years. If these lesions give rise to a myocardial infarction, this is often termed the "widow maker" because of the large area of myocardium subtended by the LAD and the high mortality associated with proximal LAD occlusion.
-
Unfractionated Heparin (UFH) is the standard bridging therapy for patients with mechanical heart valves who need to temporarily stop oral anticoagulants. Small case series have suggested that low molecular weight heparin (LMWH) may be useful for this purpose.
-
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
Platelet inhibition with clopidogrel has become an important weapon against recurrent coronary events in patients with coronary artery disease. However, recent evidence shows that patient response to clopidogrel is variable, with some patients having suboptimal inhibition of platelet aggregation.
-
Uncomplicated type B aortic dissection (origin distal to left subclavian artery) is usually treated medically. However, early mortality is 10%-12%, and is due to complications.
-
The cardiac arrest registry to enhance survival (CARES) is a registry designed to help local emergency medical system officials monitor outcomes of out-of-hospital resuscitation.
-
Since both treadmill exercise ECG and echo have independent prognostic value when studied alone, what does the ECG response add to a negative exercise echo?
-
A long-standing controversy exists regarding use of angioplasty (PCI) vs best or optimal medical therapy in subjects with stable coronary disease (CAD).
-
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
